ADReCS

Pharmaceutical Information

Drug Name	Prednisolone
Drug ID	BADD_D01831
Description	Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage	Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status	approved; vet_approved
ATC Code	A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID	DB00860
KEGG ID	D00472
MeSH ID	D011239
PubChem ID	5755
TTD Drug ID	D0D1SG
NDC Product Code	38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII	9PHQ9Y1OLM
Synonyms	Prednisolone \| Predate \| Predonine \| Di-Adreson-F \| Di Adreson F \| DiAdresonF

Chemical Information

Molecular Formula	C21H28O5
CAS Registry Number	50-24-8
SMILES	CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Hypothalamic pituitary adrenal axis suppression	05.03.04.007	0.000070%		Not Available
Foetal heart rate deceleration abnormality	02.03.02.022; 18.03.02.012	0.000035%		Not Available
Faeces soft	07.01.03.008	0.000052%		Not Available
Encapsulating peritoneal sclerosis	07.07.03.004	0.000087%		Not Available
Mouth swelling	23.04.01.020; 10.01.05.020; 07.05.04.007	0.000035%		Not Available
Intrusive thoughts	19.10.03.008	0.000052%		Not Available
Multiple organ dysfunction syndrome	08.01.03.057	0.001066%
Agitated depression	17.02.05.050; 19.15.01.007	0.000035%		Not Available
Antiphospholipid syndrome	24.01.01.029; 18.02.04.002; 10.04.01.009; 01.01.02.016	0.000035%		Not Available
Behcet's syndrome	10.02.02.015; 07.05.06.008; 06.04.05.017; 24.12.04.003; 23.06.02.004; 21.10.03.009; 15.01.01.009	0.000140%		Not Available
Bladder transitional cell carcinoma	20.03.04.003; 16.08.01.002	0.000035%		Not Available
Brief psychotic disorder, with postpartum onset	19.03.05.002; 18.06.03.001	0.000035%		Not Available
Bronchial fistula	22.03.02.011	0.000070%
Carotid artery aneurysm	24.02.04.003; 17.08.06.002	0.000035%		Not Available
Central nervous system lymphoma	18.04.04.013; 17.02.10.028; 16.20.01.005; 01.12.01.005	0.000052%		Not Available
Cholangitis acute	09.02.01.006	0.000035%		Not Available
Chronic gastritis	11.07.01.016; 10.04.04.011; 07.08.02.005	0.000035%		Not Available
Concomitant disease aggravated	08.01.03.063	0.000052%		Not Available
Diverticulum intestinal haemorrhagic	07.10.01.003; 24.07.02.043	0.000035%		Not Available
Fracture nonunion	15.08.01.004; 12.04.02.017	0.000105%		Not Available
Hallucination, olfactory	19.10.04.005	0.000052%		Not Available
Hepatic infarction	24.04.07.007; 09.01.06.017	0.000070%		Not Available
IgA nephropathy	20.05.01.016; 10.02.01.063	0.000035%		Not Available
Ileal stenosis	07.13.06.006	0.000052%
Impulsive behaviour	19.18.01.001	0.000087%		Not Available
Intestinal fistula	07.11.05.012	0.000105%		Not Available
Joint destruction	15.01.08.012	0.000035%		Not Available
Lichen sclerosus	23.03.08.006; 21.10.03.010	0.000070%		Not Available
Lupus nephritis	10.04.03.011; 20.05.02.003; 15.06.02.011	0.000070%		Not Available
Metastases to lymph nodes	01.09.01.015; 16.22.02.006	0.000052%		Not Available

The 29th Page First Pre 29 30 31 32 33 Next Last Total 36 Pages